Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftolozane/tazobactam - Merck Sharp & Dohme

Next Previous
Drug Profile

Ceftolozane/tazobactam - Merck Sharp & Dohme

Alternative Names: CXA-101/tazobactam; CXA-101/YTR-830H; CXA-201; MK-7625A; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa

Latest Information Update: 13 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer M. D. Anderson Cancer Center; Merck Sharp & Dohme
  • Class 2 ring heterocyclic compounds; Anti-infectives; Anti-inflammatories; Antibacterials; Cephalosporins; Small molecules; Sulfones; Triazoles; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
  • Registered Pyelonephritis
  • Phase II Bacterial infections

Most Recent Events

  • 14 Sep 2024 Ceftolozane/tazobactam is still in phase I MK-7625A-036 clinical trials in Ventilator-associated-pneumonia (In adolescents, In children, In infants, In neonates) in Spain, Estonia, Greece, Russia, Ukraine and the US (IV) (NCT04223752) (EudraCT2018-004704-19) (EudraCT2022-501110-56-00)
  • 14 Sep 2024 Merck Sharp & Dohme LLC completes phase I MK-7625A-036 clinical trials in Ventilator-associated-pneumonia (In adolescents, In children, In infants, In neonates) in Mexico, Chile, Colombia, Spain, Estonia, Greece, Russia, Ukraine and the US (IV) (NCT04223752) (EudraCT2018-004704-19) (EudraCT2022-501110-56-00)
  • 28 May 2024 No recent reports of development identified for phase-I development in Nosocomial-pneumonia(In adolescents, In children, In infants, In neonates) in Greece (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top